- Home
- FRPT vs IMVT Comparison
FRPT vs IMVT Comparison
Compare FRPT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPT
- IMVT
- Stock Information
- Founded
- FRPT 2004
- IMVT 2018
- Country
- FRPT United States
- IMVT United States
- Employees
- FRPT N/A
- IMVT N/A
- Industry
- FRPT Packaged Foods
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRPT Consumer Staples
- IMVT Health Care
- Exchange
- FRPT Nasdaq
- IMVT Nasdaq
- Market Cap
- FRPT 3.1B
- IMVT 2.7B
- IPO Year
- FRPT 2014
- IMVT N/A
- Fundamental
- Price
- FRPT $53.09
- IMVT $15.58
- Analyst Decision
- FRPT Buy
- IMVT Buy
- Analyst Count
- FRPT 16
- IMVT 11
- Target Price
- FRPT $118.80
- IMVT $33.88
- AVG Volume (30 Days)
- FRPT 1.5M
- IMVT 1.6M
- Earning Date
- FRPT 11-03-2025
- IMVT 11-06-2025
- Dividend Yield
- FRPT N/A
- IMVT N/A
- EPS Growth
- FRPT 28.97
- IMVT N/A
- EPS
- FRPT 0.66
- IMVT N/A
- Revenue
- FRPT $1,044,013,000.00
- IMVT N/A
- Revenue This Year
- FRPT $16.39
- IMVT N/A
- Revenue Next Year
- FRPT $13.39
- IMVT N/A
- P/E Ratio
- FRPT $83.06
- IMVT N/A
- Revenue Growth
- FRPT 19.30
- IMVT N/A
- 52 Week Low
- FRPT $52.27
- IMVT $12.72
- 52 Week High
- FRPT $164.07
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- FRPT 36.58
- IMVT 47.27
- Support Level
- FRPT $52.70
- IMVT $16.08
- Resistance Level
- FRPT $55.55
- IMVT $17.20
- Average True Range (ATR)
- FRPT 2.19
- IMVT 0.79
- MACD
- FRPT 0.15
- IMVT 0.09
- Stochastic Oscillator
- FRPT 13.12
- IMVT 38.54
About FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.